Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • illinu
    Member
    • Jul 2013
    • 55

    #1

    Preparing reference transcriptome: to or not to megablast

    A quick question here. I am constructing a reference transcriptome for DE out of 16 transcriptomes (8 control + 8 treatment) and my strategy is as follows:
    1. create a database with transcriptome 1 (random)
    2. blast transcriptome 2 to 1
    3. start creating the reference transcriptome = transcriptome 1 + unmatched transcripts from transcriptome 2
    4. create a database with the reference transcriptome
    5. blast transcriptome 3 to ref transcr.
    6. as in point 3 and so on

    At the end I will have a reference transcriptome with all the transcripts present in the 16 transcriptomes represented once.

    My questions is to use or not to use -task megablast.
    If I use megablast then the reference transcriptome is almost double in size and there might be in my view some redundancy?

    What are your thoughts...
    Thank you
  • bastianwur
    Member
    • Feb 2014
    • 98

    #2
    If your computing resources allow it: cross-assemble the transcriptome.
    Means you pool all the RNAseq samples together, and assemble it as one.
    That doesn't produce many mis-assemblies, and makes dealing with the reference a lot easier. (I'd give a reference here, but I think it's just submitted yet).

    Else: Megablast will be too strict for that purpose, I think. I'd rather use normal blastn instead.
    Last edited by bastianwur; 09-24-2014, 01:13 PM.

    Comment

    • illinu
      Member
      • Jul 2013
      • 55

      #3
      Else: Megablast will be too strict for that purpose, I think. I'd rather use normal blastn instead.
      This is exactly what I thought, too strict. So I did blastn finally.

      I didn't think about pooling all samples because the 8 control + 8 treatment are not all the same genotype but 4 different ones and among them 2 different ecotypes. Wouldn't cross assembly in this case create falsely larger transcripts? Or chimeric genes?

      Comment

      • westerman
        Rick Westerman
        • Jun 2008
        • 1104

        #4
        For combining datasets you could use Brian Bushell's 'dedupe.sh' program.

        Since you do have different genotypes, I agree that pooling all samples and re-assembling the transcriptome would cause too many false transcripts.

        But it sounds like you have already solved your problem. I would be concerned about commutative effects. In other words is starting with sample 1 and getting 1 + 2 + 3 the same as starting with sample 3 and getting 3 + 1 + 2?

        Comment

        • illinu
          Member
          • Jul 2013
          • 55

          #5
          Originally posted by westerman View Post
          I would be concerned about commutative effects. In other words is starting with sample 1 and getting 1 + 2 + 3 the same as starting with sample 3 and getting 3 + 1 + 2?
          Good point... I don't know. Actually I am looking at how other people do DE with independently assembled transcriptomes, no reference genome and different genotypes and the options are so wide that I am starting to be puzzled. It seems not too many researchers adopted my strategy, bah indeed I haven't found one reference. I am seeing people doing annotation of the de novo assemblies independently, then mapping their reads to the annotated transcriptomes and then comparing the lists. But this seems to give problems of having the same transcripts annotated differently.
          My plan was to generate this reference transcriptome (that suits my data set) and then annotate and map independently the reads of each genotype to the reference. I think with this approach I will be able to compare side by side the same genes and not have to work with maybe the same transcript being annotated differently in two lists (or 8).

          I will think about the commutative effect. How can I test this?

          Comment

          • bastianwur
            Member
            • Feb 2014
            • 98

            #6
            Originally posted by illinu View Post
            This is exactly what I thought, too strict. So I did blastn finally.

            I didn't think about pooling all samples because the 8 control + 8 treatment are not all the same genotype but 4 different ones and among them 2 different ecotypes. Wouldn't cross assembly in this case create falsely larger transcripts? Or chimeric genes?
            AFAIK not in a considerable amount, but then again that has only been tested for prokaryotes (I'd assume higher error rate for eukaryotes), and not sure with what data you're dealing with.

            Comment

            • illinu
              Member
              • Jul 2013
              • 55

              #7
              Originally posted by bastianwur View Post
              not sure with what data you're dealing with.
              It is eukariote diploid heterozygote... there could be alternative splicing due to the treatment (?)... not sure about pooling

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                by SEQadmin2



                CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                Despite this, “CRISPR helped turn genome editing from a specialized technique into
                ...
                07-31-2026, 11:01 AM
              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Yesterday, 10:13 AM
              0 responses
              13 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-31-2026, 02:55 AM
              0 responses
              26 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-24-2026, 12:17 PM
              0 responses
              20 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-23-2026, 11:41 AM
              0 responses
              19 views
              0 reactions
              Last Post SEQadmin2  
              Working...